Literature DB >> 11101196

The cardioprotective effects of a new 1,4-benzothiazepine derivative, JTV519, on ischemia/reperfusion-induced Ca2+ overload in isolated rat hearts.

K Inagaki1, Y Kihara, T Izumi, S Sasayama.   

Abstract

A new 1,4-benzothiazepine derivative, JTV519 (JTV), has strong protective effects against isoproterenol-induced myocardial injury. We investigated the effects of JTV on Ca2+ overload and on functional recovery during ischemia/reperfusion in isolated coronary-perfused rat hearts. After 30 minutes of reperfusion following 30 min of global ischemia, the % recovery of LV developed pressure was improved in a concentration-dependent manner when JTV (0.3-3.0 microM) was administered either 5 min before induction of ischemia or for 5 min at the time of reperfusion only JTV showed a negative inotropic effect only at concentrations above 3.0 microM. In indol-loaded isolated heart preparations, 0.3 microM JTV did not affect the preischemic systolic or diastolic Ca2+ levels of the Ca2+ transient as measured by the ratio of 2-wavelength fluormetry (R405/500). In contrast, it significantly reduced the increase in the ratio in the postischemic reperfusion period (% change of R405/500 from baseline: JTV(-), by 42.7 +/- 3.2%; JTV(+), by 18.4 +/- 9.1%, p < 0.05). In isolated rat ventricular myocytes with a standard patch-clamp method, we further tested the interaction of JTV with the L-type Ca2+ channel (I(Ca)). The % inhibition of the peak current of I(Ca) was 6.2 +/- 0.8% at 0.3 microM (p = n.s.), 22.0 +/- 3.3% at 1.0 microM (p < 0.05), and 59.6 +/- 1.4% at 3.0 microM (p < 0.01). Thus, the marked cardioprotection due to JTV at 0.3 microM may not be solely attributed to its inhibitory effect on the transsarcolemmal Ca2+ influx through I(Ca). In conclusion, JTV519 is a novel pharmacological agent that has been demonstrated for the first time to have clinical potential for the treatment of acute coronary syndrome by its efficacy in administration at the time of reperfusion, by its suppression of reperfusion-related intracellular Ca2+ overload with no significant interaction with I(Ca), and by its subsequent ability of strong myocardial protection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11101196     DOI: 10.1023/a:1007884905461

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  11 in total

Review 1.  Mitochondrial reactive oxygen species at the heart of the matter: new therapeutic approaches for cardiovascular diseases.

Authors:  Opher S Kornfeld; Sunhee Hwang; Marie-Hélène Disatnik; Che-Hong Chen; Nir Qvit; Daria Mochly-Rosen
Journal:  Circ Res       Date:  2015-05-22       Impact factor: 17.367

Review 2.  Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy.

Authors:  Changwon Kho; Ahyoung Lee; Roger J Hajjar
Journal:  Nat Rev Cardiol       Date:  2012-10-23       Impact factor: 32.419

3.  The effect of K201 on isolated working rabbit heart mechanical function during pharmacologically induced Ca2+ overload.

Authors:  A Kelly; E B Elliott; R Matsuda; N Kaneko; G L Smith; C M Loughrey
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

4.  JTV519 (K201) reduces sarcoplasmic reticulum Ca²⁺ leak and improves diastolic function in vitro in murine and human non-failing myocardium.

Authors:  M Sacherer; S Sedej; P Wakuła; M Wallner; M A Vos; J Kockskämper; P Stiegler; M Sereinigg; D von Lewinski; G Antoons; B M Pieske; F R Heinzel
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

5.  Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure.

Authors:  Xander H T Wehrens; Stephan E Lehnart; Steven Reiken; Roel van der Nagel; Raymond Morales; Jie Sun; Zhenzhuang Cheng; Shi-Xiang Deng; Leon J de Windt; Donald W Landry; Andrew R Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-22       Impact factor: 11.205

6.  K201 (JTV519) suppresses spontaneous Ca2+ release and [3H]ryanodine binding to RyR2 irrespective of FKBP12.6 association.

Authors:  Donald J Hunt; Peter P Jones; Ruiwu Wang; Wenqian Chen; Jeff Bolstad; Keyun Chen; Yakhin Shimoni; S R Wayne Chen
Journal:  Biochem J       Date:  2007-06-15       Impact factor: 3.857

7.  Effects of K-201 on the calcium pump and calcium release channel of rat skeletal muscle.

Authors:  Janos Almassy; Monika Sztretye; Balazs Lukacs; Beatrix Dienes; Laszlo Szabo; Peter Szentesi; Guy Vassort; Laszlo Csernoch; Istvan Jona
Journal:  Pflugers Arch       Date:  2008-05-06       Impact factor: 3.657

Review 8.  Ryanodine receptor-mediated arrhythmias and sudden cardiac death.

Authors:  Lynda M Blayney; F Anthony Lai
Journal:  Pharmacol Ther       Date:  2009-04-01       Impact factor: 12.310

Review 9.  Myocardial protection in man--from research concept to clinical practice.

Authors:  Dennis V Cokkinos; Costas Pantos
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

Review 10.  Pharmacological characteristics and clinical applications of K201.

Authors:  Noboru Kaneko; Ryuko Matsuda; Yoshihito Hata; Ken Shimamoto
Journal:  Curr Clin Pharmacol       Date:  2009-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.